Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064129 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00064129: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00064129 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064129, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of ipilimumab when given with sargramostim in treating patients with metastatic prostate cancer. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system kill more tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Ipilimumab
- BIOLOGICAL Sargramostim
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2003-05-13 |
| Est. Completion | 2012-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064129
The ClinicalTrials.gov registry entry for NCT00064129 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00064129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064129 about?
NCT00064129 is a clinical study titled "Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer". This phase I trial is studying the side effects and best dose of ipilimumab when given with sargramostim in treating patients with metastatic prostate cancer. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. C...
What is the current status of trial NCT00064129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2003-05-13. Estimated completion is 2012-10-01.
What interventions are being tested in trial NCT00064129?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Ipilimumab (BIOLOGICAL), Sargramostim (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00064129?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.